PROLIA® Non-English

PROLIA® is an injectable medication that contains denosumab, a monoclonal antibody that helps reduce bone loss in individuals with osteoporosis. By inhibiting the activity of osteoclasts, cells that break down bone tissue, PROLIA® increases bone mass and strength, making bones less likely to fracture. It is typically administered as a subcutaneous injection every six months and is used to treat conditions such as osteoporosis in postmenopausal women, osteoporosis in men at high risk for fracture, and bone loss in patients undergoing certain types of cancer treatment. PROLIA® is a well-established therapy for preventing fractures in people with low bone density.

Main Treatment Areas

• Osteoporosis in Postmenopausal Women: PROLIA® is widely used to treat osteoporosis in postmenopausal women who are at high risk of fractures due to weakened bones. It helps slow the loss of bone tissue and reduces the risk of fractures in areas like the spine, hips, and wrists.
• Osteoporosis in Men: PROLIA® is also approved to treat men with osteoporosis who are at increased risk for fractures, especially those with a history of fractures or who are undergoing long-term steroid therapy.
• Bone Loss in Cancer Treatment Patients: PROLIA® is used to treat bone loss in men undergoing androgen deprivation therapy for prostate cancer and women receiving aromatase inhibitor therapy for breast cancer. These therapies can lead to significant bone loss, and PROLIA® helps counteract this effect.

Key Benefits

• Fracture Prevention: PROLIA® significantly reduces the risk of fractures in individuals with osteoporosis by increasing bone mineral density and reducing bone resorption.
• Convenient Dosing Schedule: Unlike daily or weekly osteoporosis medications, PROLIA® is administered as an injection every six months, making it more convenient for patients and ensuring better compliance with treatment.
• Effectiveness in High-Risk Patients: PROLIA® is particularly effective in patients with a high risk of fractures, including those with a previous history of fractures or those who have not responded to other osteoporosis treatments.
• Cancer Therapy Support: PROLIA® is a valuable option for cancer patients experiencing bone loss as a side effect of hormone therapy, helping to maintain bone strength during their treatment.

Safety Information

PROLIA® is generally well-tolerated, but it may cause side effects. Common side effects include back pain, musculoskeletal pain, and high cholesterol levels. More serious side effects may include low calcium levels (hypocalcemia), serious infections, and allergic reactions. Rare but severe side effects include osteonecrosis of the jaw (ONJ) and atypical femoral fractures. It is important for patients to maintain adequate levels of calcium and vitamin D during treatment to avoid hypocalcemia. PROLIA® is not recommended for patients with hypocalcemia or those with severe kidney issues unless closely monitored by a healthcare provider. Patients should consult their healthcare provider for a complete assessment of potential risks and benefits.

PROLIA Purchase Information

For healthcare professionals and clinics looking to purchase PROLIA®, Dr Sales Direct is a trusted wholesale supplier offering competitive wholesale prices.  Sign in to access wholesale rates and bulk purchase options, ensuring you receive high-quality products at the best prices for your practice’s needs. Dr Sales Direct provides high-quality products at cost-effective prices to support your practice’s osteoporosis treatment needs.